CLAIMS

1. A pharmaceutical composition comprising a compound of the formula (1)



(1)

and an aqueous buffer, wherein the composition has a pH of from about 5 to about 6.

2. A pharmaceutical composition comprising a compound of the formula (2):



(2)

and an aqueous buffer, wherein the composition has a pH of from about 5 to about 6.

3. The pharmaceutical composition of claim 1 or claim 2, wherein the buffer is a phosphate or acetate buffer.

4. The pharmaceutical composition of any one of claims 1-3, further comprising a stabilizing agent.

5. The pharmaceutical composition of claim 4, wherein the stabilizing agent is (a) a cyclodextrin; (b) a sulfo-*n*-butyl ether derivative of β-cyclodextrin having six or seven sulfo-*n*-butyl ether groups per cyclodextrin molecule; and/or (c) a sulfo-*n*-butyl ether derivative of β-cyclodextrin which is a β-cyclodextrin having at least one -OH group that is derivatized by replacing the hydrogen atom thereof with $-(CH_2)_4-S(O)_2-O^- Z^+$ to provide a $-O-(CH_2)_4-S(O)_2-O^- Z^+$ group, where Z is sodium.

6. The pharmaceutical composition of claim 5, wherein the molar ratio between the compound and the cyclodextrin present in the composition is (a) from about 0.02:1 to about 2:1; (b) from about 0.05:1 to about 1.5:1; or (c) from about 0.5:1 to about 1:1.

7. A pharmaceutical composition comprising a compound of the formula (1):



(1)

and a cyclodextrin.

8. A pharmaceutical composition comprising a compound of the formula (2):



(2)

and a cyclodextrin.

9. The pharmaceutical composition of claim 7 or 8, wherein the cyclodextrin is (a) a sulfo-*n*-butyl ether derivative of β-cyclodextrin having six or seven sulfo-*n*-butyl ether groups per cyclodextrin molecule; and/or (b) a sulfo-*n*-butyl ether derivative of β-cyclodextrin which is a β-cyclodextrin having at least one -OH group that is derivatized by replacing the hydrogen atom thereof with $-(CH_2)_4-S(O)_2-O^- Z^+$ to provide a $-O-(CH_2)_4-S(O)_2-O^- Z^+$ group, where Z is sodium.

10. The pharmaceutical composition of any one of claims 7-9, wherein the molar ratio between the compound and the cyclodextrin present in the composition is (a) from about 0.02:1 to about 2:1; (b) from about 0.05:1 to about 1.5:1; or (c) from about 0.5:1 to about 1:1.

11. An admixture comprising a compound of the formula (1):



(1)

and a cyclodextrin, wherein the molar ratio between the compound and the cyclodextrin present in the composition is from about 0.02:1 to about 2:1.

12. An admixture comprising a compound of the formula (2):



(2)

and a cyclodextrin, wherein the molar ratio between the compound and the cyclodextrin present in the composition is from about 0.02:1 to about 2:1.

13. The admixture of claim 11 or 12, further comprising a buffering agent, preferably potassium acetate.